Infugen Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Infugen Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $375.9K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Infugen Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $375.9K Trade | TransData Nexus

Infugen Pharma Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $375.9K Total Trade · DGFT Verified

Infugen Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $375.9K across 2 products in 1 therapeutic categories. Based on 9 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Bleomycin ($300.0K), Chlorambucil ($75.9K), .

Infugen Pharma Private Limited — Export Portfolio & Destination Treemap

Infugen Pharma Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Infugen Pharma Private Limited? — Company Overview & Market Position

Infugen Pharma Private Limited, established on February 4, 1999, in Sangli, Maharashtra, India, is a privately held pharmaceutical company specializing in the export of finished pharmaceutical formulations. The company operates under the Corporate Identification Number (CIN) U24231PN1999PTC013295 and is registered with the Registrar of Companies, Pune. Initially known as Jeshika Pharma Private Limited, it rebranded to Infugen Pharma Private Limited to better reflect its global aspirations. The authorized capital stands at ₹3 million, with a paid-up capital of ₹1 million. The company's registered office is located at Yashokamalharbhat Road, Opposite Sangli Urban Co-Op Bank Ltd, Sangli, Maharashtra, 416416.

Infugen Pharma has experienced significant growth since its inception, becoming one of the fastest-growing export houses in the healthcare sector. With over 30 years of experience, the company has expanded its product portfolio to include more than 100 products, available in over 25 countries. The company's focus on contract manufacturing services has enabled it to establish a strong presence in various international markets, including North and East Africa, French West Africa, Southeast Asia, Central America, the Caribbean, and CIS countries.

What Does Infugen Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Bleomycin

Product Portfolio — Top 2 by Export Value

Infugen Pharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Bleomycin	Advanced Oncology	$300.0K	6	5.4%	3
2	Chlorambucil	Advanced Oncology	$75.9K	3	22.1%	2

Infugen Pharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $375.9K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Infugen Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Infugen Pharma operates a WHO GMP-certified oncology unit with a production capacity of 500,000 tablets, 1 million capsules, and 200,000 veterinary tablets per shift. This facility underscores the company's commitment to maintaining high-quality standards in pharmaceutical manufacturing. Additionally, Infugen collaborates with other specialized formulation manufacturing units to enhance its product offerings and ensure compliance with global quality standards.

3Key Leadership

The leadership team at Infugen Pharma Private Limited includes:

Sandeep Jagjeevan Modi: Director

Bharat Jagjivan Bhate: Director

Both directors have been with the company since its inception on February 4, 1999. Their leadership has been instrumental in steering the company towards its current position in the pharmaceutical export sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Infugen Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Infugen Pharma has made significant strides in obtaining regulatory approvals across various international markets. The company holds WHO GMP certification for its oncology unit, ensuring compliance with international manufacturing standards. Infugen has also secured product registrations in multiple countries, including Nigeria, Tanzania, Kenya, Ghana, Uganda, the Philippines, Ethiopia, Zambia, Lesotho, Sri Lanka, the Democratic Republic of Congo, Vietnam, Ivory Coast, Cambodia, Portugal, Brazil, Tajikistan, and Yemen. These approvals facilitate the company's market access in the United States, European Union, United Kingdom, Australia, and Japan, enabling it to export its pharmaceutical formulations to these regions.

2Emerging Markets

Infugen Pharma has strategically expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's product registrations in countries such as Nigeria, Tanzania, Kenya, Ghana, Uganda, the Philippines, Ethiopia, Zambia, Lesotho, Sri Lanka, the Democratic Republic of Congo, Vietnam, Ivory Coast, Cambodia, Portugal, Brazil, Tajikistan, and Yemen have facilitated its market penetration in these regions. The WHO GMP certification for its oncology unit further enhances the company's credibility and facilitates access to these markets.

Geographic Strategy

Infugen Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 2026, there is no publicly available information indicating that Infugen Pharma Private Limited has FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or a history of FDA inspections. The company's primary focus appears to be on markets outside the United States, as evidenced by its product registrations in countries such as Nigeria, Tanzania, Kenya, Ghana, Uganda, the Philippines, Ethiopia, Zambia, Lesotho, Sri Lanka, the Democratic Republic of Congo, Vietnam, Ivory Coast, Cambodia, Portugal, Brazil, Tajikistan, and Yemen.

2WHO & EU GMP

Infugen Pharma's oncology unit has been accredited with WHO GMP certification, ensuring compliance with international manufacturing standards. This certification enhances the company's credibility and facilitates access to global markets. However, there is no publicly available information indicating that Infugen holds EU GMP certificates or has EDQM status.

3CDSCO & Indian Regulatory

Infugen Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Infugen Pharma Private Limited operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share data is not publicly available, the company's focus on contract manufacturing services and its product portfolio, which includes tablets, capsules, IV infusions, antibiotics, and oncology drugs, position it as a significant player in the market. The company's WHO GMP certification for its oncology unit and product registrations in multiple countries enhance its competitive edge.

2Key Differentiators

Infugen Pharma's key differentiators include its WHO GMP-certified oncology unit, which ensures high-quality manufacturing standards, and its extensive product portfolio of over 100 products available in more than 25 countries. The company's strategic focus on contract manufacturing services and its presence in diverse international markets further distinguish it from competitors.

3Strategic Position

Infugen Pharma's current strategic direction emphasizes contract manufacturing services, with a focus on pharmaceutical formulations and medical devices. The company's expansion into various international markets, including North and East Africa, French West Africa, Southeast Asia, Central America, the Caribbean, and CIS countries, reflects a strategy aimed at global growth and market diversification. The WHO GMP certification for its oncology unit underscores the company's commitment to meeting international quality standards, positioning it favorably for future growth opportunities.

Buyer Due Diligence Brief — Evaluating Infugen Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Infugen Pharma Private Limited has demonstrated a strong track record in pharmaceutical manufacturing and export, with a product portfolio that includes tablets, capsules, IV infusions, antibiotics, and oncology drugs. The company's WHO GMP-certified oncology unit and product registrations in multiple countries indicate a commitment to quality and regulatory compliance. The company's focus on contract manufacturing services and its presence in diverse international markets further enhance its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Infugen Pharma Private Limited as a supplier:

WHO GMP Certification: To ensure compliance with international manufacturing standards.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Infugen Pharma Private Limited

How many pharmaceutical products does Infugen Pharma Private Limited export from India?

Infugen Pharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Bleomycin ($300.0K), Chlorambucil ($75.9K). Total export value is $375.9K.

What is Infugen Pharma Private Limited's total pharmaceutical export value?

Infugen Pharma Private Limited's total pharmaceutical export value is $375.9K, based on 9 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Infugen Pharma Private Limited cover?

Infugen Pharma Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full Infugen Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.